Jan 2011

AHF Advocates For Lower-Income Patients

AHF initiates an advocacy campaign to end the negative impacts of high drug costs on the U.S. AIDS Drug Assistance Program, which helps lower-income people pay for life-saving HIV treatment. ADAP’s costs are spiraling out of control due to exorbitant prices pushed by pharmaceutical companies. Patients, as a result, are placed on waitlists for crucial funding to pay for their medications. During the campaign, AHF targets pharmaceutical giants Gilead Sciences and Johnson & Johnson, whose policies make HIV treatment less accessible to the public.